Table 4 Summary of non-inferiority of live SARS-CoV-2 neutralizing antibody seroconversion rate (SCR) between adolescents (12–<18 years) and young adults (20–30 years) who received MVC-COV1901.

From: Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial

Per protocol set (PPS) Visit 6 (Day 57)

Adolescents of MVC-COV1901 (N = 334)

Young Adults of MVC-COV1901 (N = 210)

Difference adolescent/young adults

P-value

SCR, n (%)

334 (100%)

210 (100%)

−0.0%

N/A

95% CIa

98.90–100.00%

98.26–100.00%

−0.00% to 0.00%

 
  1. aCI calculated using a normal approximation for the binomial proportion of #.
Back to article page